Literature DB >> 5321221

Ethyl chlorophenoxyisobutyrate (CPIB) effects in juvenile-onset diabetes mellitus.

T S Danowski, R E Cohn, N R Limaye, J F Novak, R Saul, J H Sunder, C Moses.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1965        PMID： 5321221     DOI： 10.1002/cpt196566716

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  4 in total

1.  Effect of clofibrate on glucose tolerance in maturity onset diabetes.

Authors:  D Barnett; J G Craig; D S Robinson; M P Rogers
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

2.  Halofenate versus clofibrate in the management of true diabetes insipidus.

Authors:  A Gattereau; J Davignon; M Verdy; W Lewis
Journal:  Can Med Assoc J       Date:  1974-06-08       Impact factor: 8.262

3.  Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.

Authors:  J C Daubresse; D Daigneux; M Bruwier; A Luyckx; P J Lefebvre
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

4.  Clofibrate in insulin-dependent diabetes.

Authors:  C Twomey; A Bloom
Journal:  Ir J Med Sci       Date:  1979-12       Impact factor: 1.568
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.